Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB) will participate in two investor conferences in late 2025 with senior management presenting in fireside chats.

• Jefferies Global Healthcare Conference (London) — Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will speak on Nov 18, 2025 at 11:00 a.m. GMT (6:00 a.m. ET).
• Piper Sandler 37th Annual Healthcare Conference — the same executives will speak on Dec 2, 2025 at 11:30 a.m. ET.

Live webcasts will be available on the company Investors Events page, and replay files will be archived there for 30 days. Institutional investors seeking one-on-one meetings should contact their Jefferies or Piper Sandler representatives.

Solid Biosciences (NASDAQ: SLDB) announced that SGT-003, its investigational gene therapy for Duchenne muscular dystrophy, was granted an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP) on November 6, 2025. The Passport activates MHRA and ILAP partner agencies to develop a product-specific roadmap intended to accelerate regulatory timelines and patient access in the UK.

SGT-003 is one of the first three products in the new ILAP. Clinical development continues: the Phase 1/2 INSPIRE DUCHENNE trial is enrolling across 15 sites in the US, UK, Italy and Canada, and Solid has activated the first site and begun screening for the ex-US Phase 3 IMPACT DUCHENNE trial.

Solid Biosciences (Nasdaq: SLDB) announced on Nov. 4, 2025 that it granted a total of 26,550 restricted stock units (RSUs) to two newly hired employees as inducements under its 2024 Inducement Stock Incentive Plan.

The RSUs vest in four equal annual installments on each one‑year anniversary of the grant date through the fourth anniversary, and vesting is subject to each employee's continued service. The grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (Nasdaq: SLDB) reported Q3 2025 updates: 23 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial as of Oct 31, 2025, with an expectation to reach 30 participants by early 2026. The company plans an FDA meeting in H1 2026 to discuss potential registrational and accelerated pathways. Day 90 biopsy data (N=10) showed mean microdystrophin 58% (western blot and mass spectrometry) and mean beta-sarcoglycan 50%. Strong correlations observed with DAPC components (r=0.95) and CK reductions (r=-0.78). Cardiac markers trended toward normalized LVEF at Day 180 (N=8). Cash position: $236.1M, runway into H1 2027.

Solid Biosciences (Nasdaq: SLDB) announced it will participate in two investor conferences in November 2025. Dr. Gabriel Brooks, Chief Medical Officer will join a panel titled “Precision Medicine: DMD, FA, and Beyond” on November 6, 2025 at 1:40 p.m. ET at the Truist Securities BioPharma Symposium. Management will hold one-on-one investor meetings at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 10, 2025. Institutional investors should contact their Truist or Guggenheim representatives to request meetings.

Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company focusing on neuromuscular and cardiac diseases, has granted 116,150 restricted stock units (RSUs) to four new employees. The RSUs will vest equally over four years, with 25% vesting on each anniversary of the grant date.

The equity awards were issued under the company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.

Solid Biosciences (NASDAQ:SLDB), a precision genetic medicines company, will present data from its neuromuscular and cardiac programs at two major scientific conferences in October 2025. The company will participate in the World Muscle Society (WMS) Annual Congress in Vienna and the European Society of Gene & Cell Therapy (ESGCT) Annual Congress in Seville.

The presentations include an oral update on the INSPIRE DUCHENNE Phase 1/2 study of SGT-003 for Duchenne Muscular Dystrophy, and multiple poster presentations covering muscle integrity biomarkers, gene therapy developments, and cardiac research. The company will showcase data demonstrating the potential of their proprietary AAV-SLB101 capsid technology.

Solid Biosciences (NASDAQ:SLDB) will present data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, their next-generation gene therapy for Duchenne muscular dystrophy, at the 26th Annual Scientific Meeting of Neuromuscular Study Group (NMSG) in Italy.

The presentations will showcase Day 90 biopsy data and updated safety data as of August 12, 2025. The company highlights SGT-003's favorable liver tolerability and encouraging early biomarker signals. Additionally, their AAV-SLB101 capsid technology has been licensed to over 25 companies and institutions for targeted gene therapy applications.

Three poster presentations will be delivered on September 26, 2025, covering the INSPIRE DUCHENNE study updates, safety evaluation, and AAV-SLB101 insights.

Solid Biosciences (NASDAQ:SLDB) has entered into a non-exclusive worldwide licensing agreement with Kinea Bio for its proprietary next-generation capsid, AAV-SLB101. The agreement allows Kinea Bio to use AAV-SLB101 for developing KNA-155, a gene therapy targeting dysferlinopathy, a form of limb-girdle muscular dystrophy.

Under the agreement, Solid will receive an upfront payment and is eligible for development and sales milestones, plus tiered royalties on net sales. The AAV-SLB101 capsid has demonstrated enhanced muscle tropism and reduced liver biodistribution in preclinical studies and early clinical data from the ongoing Phase 1/2 INSPIRE DUCHENNE trial, where it has been well-tolerated in 15 participants as of August 12, 2025.

This marks another successful partnership for Solid's AAV-SLB101 platform, with over 25 agreements and licenses executed to date.